https://www.selleckchem.com/pr....oducts/dihydroethidi
5%) met the criteria of low-risk group, and 63, 41, 43, and 15 patients were categorized in CTV D 50-60 Gy, 60-70 Gy, 70-80 Gy, and 80 Gy, respectively. While 4-y progression-free survival ranged from 66 to 80%, 4-y local control was consistently over 90% in every dose group. Rectum and bladder D and incidence of late adverse events decreased as CTV D decreased. The low-risk patients achieved favorable local control with CTV D 80 Gy. A personalized treatment strategy based on tumor response could also be adopted for cerv
Like
Comment
Share
